Brief: Cullinan Therapeutics Says Phase 1 CLN-049 Monotherapy Demonstrates Promising Efficacy

Cullinan Therapeutics

08/12/2025 16:17

Dec 8 (Reuters) - Cullinan Therapeutics Inc CGEM.O:

CULLINAN THERAPEUTICS INC - PHASE 1 CLN-049 MONOTHERAPY DEMONSTRATES PROMISING EFFICACY

Source text: ID:nGNX7qfNsN

Further company coverage: CGEM.O

 ((Reuters.Briefs@thomsonreuters.com;))